Roivant Sciences(ROIV) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update BASEL, Switzerland and LONDON and NEW YORK, August 8, 2024 – Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2024, and provided a business update. • Immunovant completed enrollment in batoclimab pivotal myasthenia gravis (MG) trial; topline results and initiation of a potentially registrational program in MG for IMVT-1402 on track for fiscal ...